Opthea

The gift of sight is something many take for granted—until it starts to fade. Vision loss, particularly from conditions like wet AMD, can impact independence, quality of life, and even longevity. We believe that the gift of superior vision can be life-changing to people affected by blinding eye diseases. “Superior vision empowers individuals and their families to pursue their passions. At Opthea, we are dedicated to pioneering innovation by pushing the boundaries of what’s possible to improve sight.” Fred Guerard, PharmD Chief Executive Officer ⏩ Check out Opthea’s new website https://opthea.com/ for valuable information about why superior visual outcomes matter, and why sozinibercept has the potential to transform the current standard of care in wet AMD. #Opthea #GiftOfSight #LoveYourEyes #MacularDegeneration #AMDResearch #WetAMD #DME #Retina #Ophthalmology #MedicalEducation #BioPharma

Opthea today announced that 24-week data from its Phase 2b trial of sozinibercept in a subgroup of wet AMD patients with polypoidal choroidal vasculopathy (PCV) have been published in the peer-reviewed journal Ophthalmololgy Science. PCV is a complex and aggressive subtype of wet AMD and a major cause of vision loss particularly in Asian populations. The results described in the paper “Sozinibercept (anti-VEGF-C/D) combined with ranibizumab for polypoidal choroidal vasculopathy: Phase 2b predefined subgroup analysis” https://lnkd.in/gMhQTp7d showed greater gains in best-corrected visual acuity (BCVA) with more favorable anatomic outcomes for sozinibercept combination therapy compared to ranibizumab monotherapy.   Opthea thanks and congratulates the co-authors Gemmy Cheung, Tim Jackson, Charles Wykoff, Arshad M. Khanani, Ian Leitch, Megan Baldwin and Jason S. Slakter, MD for all their clinical and scientific contributions in getting this important sozinibercept Phase 2b clinical data published. #Opthea #maculardegeneration #retina #AMDResearch #wetAMD #DME #ophthalmology #medicaleducation #biopharma #biotech #eyehealth #innovation #retinaspecialists #sozinibercept #superiorvision #clinicaltrialresults

Vision has a profound impact on daily life. It enables us to live full and healthy lives and perform activities of daily living like reading, driving, and navigating the world. On the contrary, vision loss can lead to a loss of independence, social isolation, depression, and an increased risk of falls and injury. “There is nothing more important than giving the gift of sight to my patients. Additional vision and the opportunity to see 20/40 or better means they can take care of themselves, live more independently, enjoy life, and do what they love. It also means they have a lower risk of falling and being injured, they stay socially connected and maintain their mental health. Every letter counts when it comes to improving vision.” Arshard M. Khanani, MD, MA, FASRS Chief Medical Advisor Check out Opthea’s new website https://opthea.com/ for valuable information about why superior visual outcomes matter and why sozinibercept has the potential to transform the current standard of care in wet AMD. #Opthea #GiftOfSight #LoveYourEyes #MacularDegeneration #AMDResearch #WetAMD #DME #Retina #Ophthalmology #MedicalEducation #BioPharma

CEO Frederic Guerard recently spoke with Alan Kohler of the Intelligent Investor about Opthea's lead product candidate, sozinibercept, ahead of the anticipated Phase 3 topline data readouts from COAST and ShORe in wet AMD. Both trials have been designed to evaluate the safety and superior efficacy of sozinibercept combination therapy versus standard-of-care anti-VEGF-A therapies alone. Sozinibercept -- a novel, first-in-class VEGF-C/D ’trap’ inhibitor -- is the only product in late-stage clinical development targeting superior vision gains in wet AMD. For patients with wet AMD, better vision is fundamental to living fuller and healthier lives.

Opthea announced the publication entitled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type” https://buff.ly/41lUPiI reporting pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naïve patients with wet AMD. Opthea thanks and congratulates the authors Charles Wykoff , @Timothy Jackson, Clare ⁛ Price, Megan Baldwin, Ian Leitch and Jason S. Slakter, MD for their hard work in getting this important sozinibercept Phase 2b clinical data published. For more details, please read the press release: https://buff.ly/0dhshWo #Opthea #maculardegeneration #retina #AMDResearch #wetAMD #DME #ophthalmology #medicaleducation #biopharma #biotech #eyehealth #innovation #retinaspecialists #sozinibercept #superiorvision #clinicaltrialresults

Opthea today announced financial results for the six months ended December 31, 2024, and highlighted recent corporate and clinical updates. The Company is making significant progress on its mission to deliver superior vision to wet AMD patients enabling them to live fuller and healthier lives.   For more details, please read the press release: https://lnkd.in/e5VP3iGm     #Opthea #maculardegeneration #AMDResearch #wetAMD #DME #ophthalmology #medicaleducation #biopharma #eyehealth #innovation #retinaspecialists #sozinibercept #superiorvision #Phase3clinicaltrial

Opthea’s PPQ campaign consisted of the successful production of three consecutive commercial-scale drug product batches required to further validate Opthea’s manufacturing process in preparation for a potential biologics license application (BLA) filing and commercialization of sozinibercept in wet AMD.   For more details, please read the press release: https://lnkd.in/eJWWCfF7   #Opthea #maculardegeneration #AMDResearch #wetAMD #DME #ophthalmology #medicaleducation #biopharma #eyehealth #innovation #retinaspecialists #sozinibercept #superiorvision #Phase3clinicaltrial #BLAfiling

Thank you Citeline David Wild for speaking with Opthea CEO Frederic Guerard about novel treatment approaches for wet AMD and why superior visual outcomes matter for patient’s quality and quantity of life.  “Opthea, for example, is developing a novel combination therapy approach targeting VEGF-C and VEGF-D pathways, positioning its candidate, sozinibercept, as a treatment to enhance the efficacy of Lucentis. ‘It’s been known for a very long time that VEGF C and D play an active role in promoting abnormal blood vessel growth that appears in the back of the eye and leak fluid in wet AMD,’ Opthea’s CEO Fred Guerard, who was previously worldwide head of ophthalmology at Novartis, told In Vivo. … The finding of superiority in visual acuity will be a differentiator for the company, should the drug be approved. A meta-analysis published in The Lancet in 2021 established a clear link between vision loss and mortality and quantified the correlation between decreasing vision and risk of death. Referring to the study and the 5.7-letter superiority of sozinibercept over Lucentis, Guerard said: ‘You have a 16% increase in mortality per letter you lose every year, compared to someone with normal vision, so it is really solving not only for quality of life, but for quantity of life.’ The company is conducting two Phase III trials, each with approximately 1,000 patients, comparing the combination of sozinibercept with Lucentis to Eylea alone in one trial and Lucentis alone in the other. Results are expected this year.” Read the article: https://lnkd.in/eDwQ9EPi #Opthea #maculardegeneration #AMDResearch #wetAMD #DME #ophthalmology #medicaleducation #biopharma #eyehealth #innovation #retinaspecialists #sozinibercept #superiorvision #Phase3clinicaltrials

Congratulations Arshad M. Khanani for receiving the prestigious J. Singerman medal at the Macula Society 2025 meeting.    #Opthea #maculardegeneration #AMDResearch #wetAMD #DME #ophthalmology #medicaleducation #biopharma #eyehealth #innovation #retinaspecialists #sozinibercept #superiorvision #MaculaSociety2025

Opthea announced that it has completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatment of wet AMD. The topline results from both trials are anticipated in early Q2 CY25 (COAST) and mid-CY25 (ShORe). For more details, please read the press release: https://lnkd.in/ebJxp7Hu #Opthea #maculardegeneration #AMDResearch #wetAMD #DME #ophthalmology #medicaleducation #biopharma #eyehealth #innovation #retinaspecialists #sozinibercept #superiorvision #Phase3clinicaltrial